Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDSNASDAQ:EFTROTCMKTS:FPMIOTCMKTS:GWHP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDSAridis Pharmaceuticals$0.00-66.7%$0.00$0.00▼$0.08$5K12.097,606 shs2,660 shsEFTReFFECTOR Therapeutics$0.00+100.0%$0.00$0.00▼$1.47$1K0.422,761 shs1,501 shsFPMIFluoroPharma Medical$0.00$0.00▼$0.00$3K0.212,470 shsN/AGWHPGlobal WholeHealth Partners$0.00$0.00▼$0.00$10KN/AN/AN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDSAridis Pharmaceuticals0.00%0.00%0.00%0.00%-99.84%EFTReFFECTOR Therapeutics0.00%+100.00%0.00%0.00%-99.99%FPMIFluoroPharma Medical0.00%0.00%0.00%0.00%0.00%GWHPGlobal WholeHealth Partners0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFPMIFluoroPharma MedicalN/AN/AN/AN/AN/AN/AN/AN/AGWHPGlobal WholeHealth PartnersN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDSAridis Pharmaceuticals 0.00N/AN/AN/AEFTReFFECTOR Therapeutics 0.00N/AN/AN/AFPMIFluoroPharma Medical 0.00N/AN/AN/AGWHPGlobal WholeHealth Partners 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDSAridis Pharmaceuticals$3.09M0.00N/AN/AN/A∞EFTReFFECTOR Therapeutics$3.55M0.00N/AN/A($1.94) per share0.00FPMIFluoroPharma MedicalN/AN/AN/AN/AN/AN/AGWHPGlobal WholeHealth Partners$10K0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDSAridis Pharmaceuticals-$30.37MN/A0.00∞N/AN/AN/AN/AN/AEFTReFFECTOR Therapeutics-$35.81M-$13.08N/A∞N/AN/AN/AN/A7/28/2025 (Estimated)FPMIFluoroPharma MedicalN/AN/A0.00N/AN/AN/AN/AN/AN/AGWHPGlobal WholeHealth Partners-$5.16MN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AFPMIFluoroPharma MedicalN/AN/AN/AN/AN/AGWHPGlobal WholeHealth PartnersN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDSAridis Pharmaceuticals9.65%EFTReFFECTOR Therapeutics57.67%FPMIFluoroPharma MedicalN/AGWHPGlobal WholeHealth PartnersN/AInsider OwnershipCompanyInsider OwnershipARDSAridis Pharmaceuticals5.50%EFTReFFECTOR Therapeutics4.70%FPMIFluoroPharma Medical36.90%GWHPGlobal WholeHealth Partners10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDSAridis Pharmaceuticals3053.32 million50.39 millionNot OptionableEFTReFFECTOR Therapeutics104.70 million4.48 millionNo DataFPMIFluoroPharma Medical427.58 million17.40 millionNot OptionableGWHPGlobal WholeHealth Partners6143.88 million129.07 millionNot OptionableFPMI, ARDS, GWHP, and EFTR HeadlinesRecent News About These CompaniesInvestors' comments on global stocks routAugust 7, 2024 | reuters.comGlobal Wholehealth Partners CorpApril 5, 2024 | morningstar.comBoston Partners Global Equity InstlMarch 19, 2024 | morningstar.comGlobal WholeHealth Partners Corporation (GWHP)February 22, 2024 | finance.yahoo.comThe Top 10September 13, 2023 | fortune.comOfficial Marketing PartnersJune 17, 2023 | pgatour.comBoston Partners Global Long/Short InvFebruary 17, 2023 | morningstar.comAutomobile Association partners with VFS Global to make it easier for travellers to access international driving permitsNovember 19, 2022 | iol.co.zaHCLTech partners with Purdue Global for higher education programOctober 16, 2022 | timesofindia.indiatimes.comOP Jindal Global University partners with Seattle University School of Law for student exchange programmeOctober 2, 2022 | financialexpress.comBehind the numbers: How we analyzed Gates' and partners' global influenceSeptember 22, 2022 | politico.comGlobal Wholehealth Partners Corp.June 16, 2022 | wsj.comSan Clemente Man Among 5 Charged in Alleged Stock Market ‘Pump-and-Dump' SchemeFebruary 17, 2022 | msn.comGlobal WholeHealth Partners declares stock dividendJanuary 13, 2022 | seekingalpha.comGlobal Wholehealth Partners Dividend Per Share (TTM)December 18, 2021 | ycharts.comGlobal Wholehealth Partners Year to Date Total Returns (Daily)December 18, 2021 | ycharts.comGlobal Wholehealth Partners EPS Diluted (5 Year Growth)December 18, 2021 | ycharts.comGlobal WholeHealth Partners Corp.’s (OTC: GWHP) Newly Designed Tests Are Now Ready for the Launch Into the Retail Marketplace and is Ready to Start the Sales to the Online Companies Approved as Stated in the 8K Filing 08/03/2021November 30, 2021 | finance.yahoo.comGlobal WholeHealth Partners Corp. (OTC: GWHP) Signs a Binding MOU With Pan Probe Biotech and AvantGen to Develop the Newest COVID-19 Antigen Test on the Market: 8K Filed on 09/21/2021October 25, 2021 | finance.yahoo.comGlobal WholeHealth Partners Corp (OTC: GWHP) Proudly Announces Its New Manufacturing Facility Which is Able to Triple the Production Volume for the Potential Sales from Walmart, Amazon, eBay and Shopify as Stated in the 8K Filing 08/03/2021October 19, 2021 | finance.yahoo.comNew MarketBeat Followers Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingPfizer's 7.5% Dividend: Income Haven or House of Cards?By Jeffrey Neal Johnson | May 23, 2025View Pfizer's 7.5% Dividend: Income Haven or House of Cards?Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumBy Jeffrey Neal Johnson | May 22, 2025View Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumFPMI, ARDS, GWHP, and EFTR Company DescriptionsAridis Pharmaceuticals NASDAQ:ARDS$0.0001 0.00 (-66.67%) As of 06/6/2025 12:21 PM EasternAridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.eFFECTOR Therapeutics NASDAQ:EFTR$0.0002 +0.00 (+100.00%) As of 06/6/2025 12:44 PM EasterneFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.FluoroPharma Medical OTCMKTS:FPMIFluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.Global WholeHealth Partners OTCMKTS:GWHPGlobal WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
